Area of interest

The Center for Integrative Chemical Biology and Drug Discovery (CICBDD) was created with the mission of bringing dedicated medicinal chemistry expertise to bear on biological targets of therapeutic relevance under investigation by UNC faculty. Synthetic and computational chemists, assay development and compound profiling scientists work in the Center and create dedicated, multidisciplinary project teams with other groups on campus in order to progress targets through the drug discovery and development process.

Stephen Frye is a Fred Eshelman Distinguished Professor in the Division of Chemical Biology and Medicinal Chemistry in the UNC Eshelman School of Pharmacy and Director of the Center for Integrative Chemical Biology and Drug Discovery at UNC-Chapel Hill. He is also the lead principal investigator for the North Carolina Comprehensive Chemical Biology Center – a UNC-based, NCI designated center that engages in oncology drug discovery.

Additionally, Stephen has defined the overall direction of the CICBDD in the chemical biology of chromatin regulation, published the first papers on small molecule ligands for methyl-lysine binding domains, and developed a large network of collaborators to increase the annotation and utility of its chemical probes.

Awards and Honors

1993 CEOs Award, Glaxo Research Institute (Special award for leadership of the 5 alpha-reductase project that led to Avodart GSK marketed product)

American Chemical Society, Organic Division Fellowship 1986-87

1986 University of North Carolina, Off Campus Graduate Fellowship

1985-86 University of North Carolina, Board of Governors Fellowship in Science and Technology

1984 University of North Carolina, Department of Chemistry, Dobbins Fellowship

1983 University of North Carolina, Department of Chemistry, Reilley Fellowship

1983 Graduated summa cum laude from NCSU